INBX — Inhibrx Biosciences, Inc.
—
Nasdaq ·
Health Care ·
Biotechnology ·
CIK 2007919 ·
Last close
$82.05
Market Cap
$1.20B
52W High
$150.98
52W Low
$77.50
ADV30
310,820
Next earnings
2026-08-12
Quarterly Fundamentals
Revenues vs Net Income (last 4 Q)
Assets vs Liabilities (last 4 Q)
| Period | Revenues | GrossProfit | OpIncome | NetIncome | Assets | Cash | Liabilities |
|---|---|---|---|---|---|---|---|
| Mar 2026 | 0 | — | -30,927,000 | -33,441,000 | 183,967,000 | 161,657,000 | 205,002,000 |
| Dec 2025 | 0 | — | -30,923,000 | -32,834,000 | 146,478,000 | 124,220,000 | 138,485,000 |
| Sep 2025 | 0 | — | -33,812,000 | -35,256,000 | 177,471,000 | 153,088,000 | 140,641,000 |
| Jun 2025 | 1,300,000 | — | -27,389,000 | -28,654,000 | 212,118,000 | 186,567,000 | 143,559,000 |
Cashflow TTM (yfinance, fills SEC gap)
Operating CF
$-131,925,000
Investing CF
$-7,000
Financing CF
$77,069,000
CapEx
$-294,000
Dividends Paid
—
Buybacks
—
EPS Diluted TTM
$-8.39
As of
2026-06-07
Balance + Analyst (yfinance extras)
Retained Earnings
$-279,628,000
Inventory
—
Receivables
$186,000
ST Investments
—
EBIT TTM
$-117,167,000
Pretax Income TTM
$-130,183,000
Interest Exp TTM
$13,016,000
Analysts
2
Yahoo Snapshot (yfinance, live)
Total Revenue
$1,300,000
EBITDA
$-120,706,000
Free Cash Flow
$-89,107,872
Enterprise Value
$1,223,011,840
Total Cash
$161,656,992
Total Debt
$180,898,000
Shares Out
14,671,186
Trailing EPS
$-8.39
Book Value
$-1.44
ROE
-354.7%
ROA
-36.1%
Div Yield
—
Annual Trend (SEC EDGAR, last 4y)
Revenues vs Net Income (last 4y)
| FY end | Revenues | OpIncome | NetIncome | Assets | Liabilities | Equity | OCF |
|---|---|---|---|---|---|---|---|
| Dec 2025 | 1,300,000 | -135,025,000 | -140,055,000 | 146,478,000 | 138,485,000 | — | -129,794,000 |
| Dec 2024 | 200,000 | -331,448,000 | 1,687,572,000 | 180,767,000 | 47,183,000 | — | -194,409,000 |
| Dec 2023 | 1,800,000 | -219,221,000 | -241,361,000 | 307,893,000 | 264,390,000 | — | -193,309,000 |
| Dec 2022 | 1,301,000 | -115,323,000 | -115,325,000 | 16,645,000 | 23,945,000 | — | -90,811,000 |
TTM Snapshot
Revenues TTM
$119,000
NetIncome TTM
$-95,653,000
OpCashFlow TTM
$0
Assets (Latest)
$180,767,000
Forward EPS
$-6.30
Peers — same industry
| Ticker | Name | Market Cap | Last | Daily % |
|---|---|---|---|---|
| NVAX | NOVAVAX INC | $1.20B | $7.32 | — |
| IMTX | Immatics N.V. | $1.18B | $8.66 | — |
| VOR | Vor Biopharma Inc. | $1.15B | $21.15 | — |
| MGTX | MeiraGTx Holdings plc | $1.09B | $11.79 | — |
| ALVO | Alvotech | $1.39B | $4.12 | — |
News headlines (Yahoo Finance, 1h cache)
Inhibrx Announces Amended Loan Agreement with Oxford Finance, Expanding Total Facility to $500.0 Million
2026-07-16 13:00 · Yahoo
Are You Looking for a Top Momentum Pick? Why Inhibrx Biosciences, Inc. (INBX) is a Great Choice
2026-07-09 16:00 · Yahoo
Inhibrx Announces U.S. FDA Acceptance of BLA for Ozekibart in Patients with Conventional Chondrosarcoma
2026-06-15 13:15 · Yahoo
Inhibrx Reports First Quarter 2026 Financial Results
2026-05-14 20:02 · Yahoo
Inhibrx Biosciences (INBX) Announces Positive Interim Results From Phase 2 Portion of HexAgon Study
2026-05-14 16:52 · Yahoo
Should Positive INBRX-106 Phase 2 Head and Neck Data Require Action From Inhibrx Biosciences (INBX) Investors?
2026-05-12 14:12 · Yahoo
Merck Broadens KEYTRUDA Collaborations As Patent Expiry Pressure Builds
2026-05-12 10:07 · Yahoo
Inhibrx Biosciences’ INBRX-106 Combo Tops KEYTRUDA Alone in Phase 2 Cancer Study
2026-05-11 16:08 · Yahoo
This Biotech Stock Surges After Positive Cancer Trial Results. What to Know.
2026-05-11 15:51 · Yahoo
Inhibrx Reports Interim Phase 2 Data for INBRX-106 in First-Line HNSCC; Initial Results Demonstrate Potential Costimulatory Benefit Over PD-1 Monotherapy
2026-05-11 12:00 · Yahoo
Recent Insider Activity
No insider activity indexed for this ticker.